Skip to content
The Policy VaultThe Policy Vault

Tafinlar (dabrafenib) — Cigna

Histiocytic Neoplasm

Initial criteria

  • Patient has Langerhans cell histiocytosis OR Erdheim-Chester disease
  • Patient has BRAF V600 mutation-positive disease

Approval duration

1 year